The importance of multidisciplinary translational clinical trials is obvious; however, making them work is complex and challenging. Here I present an argument for designing and implementing multidisciplinary mechanistic trials and present the lessons our team at the Massachusetts General Hospital Cancer Center has learned from two such trials in cancer patients with locally advanced rectal carcinomas and recurrent glioblastomas.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
6-Gingerol stabilized the p-VEGFR2/VE-cadherin/β-catenin/actin complex promotes microvessel normalization and suppresses tumor progression
Journal of Experimental & Clinical Cancer Research Open Access 02 July 2019
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med. 10, 145–147 (2004).
Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83–95 (2007).
Jain, R. K. Taming vessels to treat cancer. Sci. Am. 298, 56–63 (2008).
Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62 (2005).
Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Med. 7, 987–989 (2001).
Yuan, F. et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl Acad. Sci. USA 93, 14765–14770 (1996).
Jain, R. K. et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc. Natl Acad. Sci. USA 95, 10820–10825 (1998).
Hansen-Algenstaedt, N. et al. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res. 60, 4556–4560 (2000).
Lee, C. G. et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60, 5565–5570 (2000).
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D. & Jain, R. K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416, 279–280 (2002).
Tong, R. T. et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64, 3731–3736 (2004).
Winkler, F. et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1 and matrix metalloproteinases. Cancer Cell 6, 553–563 (2004).
Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186 (1971).
Chen, W. et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F]fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol. 25, 4714–4721 (2007).
Fine, H. A. et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol. 18, 708–715 (2000).
Herbst, R. S. et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J. Clin. Oncol. 20, 3804–3814 (2002).
Ince, W. L. et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J. Natl Cancer Inst. 97, 981–989 (2005).
Jubb, A. M. et al. Impact of vascular endothelial growth factor-A expression, thrombospondin 2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol. 24, 217–227 (2006).
Lee, L. et al. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother. Pharmacol. 57, 761–771 (2006).
Liu, G. et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: Results from a phase I study. J. Clin. Oncol. 23, 5464–5473 (2005).
Mancuso, P. et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108, 452–459 (2006).
Morgan, B. et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol. 21, 3955–3964 (2003).
Motzer, R. J. et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16–24 (2006).
Mross, K. et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur. J. Cancer 41, 1291–1299 (2005).
Norden-Zfoni, A. et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin. Cancer Res. 13, 2643–2650 (2007).
Provenzale, J. M. et al. Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms. Am. J. Roentgenol. 187, 1036–1042 (2006).
Vredenburgh, J. J. et al. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. J. Clin. Oncol. 24 (June 20 Suppl.) 1506 (2006).
Wedam, S. B. et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 24, 769–777 (2006).
Xiong, H. Q. et al. A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest. New Drugs 22, 459–466 (2004).
Boucher, Y., Kirkwood, J. M., Opacic, D., Desantis, M. & Jain, R. K. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res. 51, 6691–6694 (1991).
Boucher, Y., Salehi, H., Witwer, B., Harsh, G. R. 4th & Jain, R. K. Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br. J. Cancer 75, 829–836 (1997).
Less, J. R. et al. Interstitial hypertension in human breast and colorectal tumors. Cancer Res. 52, 6371–6374 (1992).
Roh, H. D. et al. Interstitial hypertension in carcinoma of uterine cervix in patients: possible correlation with tumor oxygenation and radiation response. Cancer Res. 51, 6695–6698 (1991).
Padera, T. et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296, 1883–1886 (2002).
Willett, C. G. et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J. Clin. Oncol. 23, 8136–8139 (2005).
Duda, D. G., Cohen, K. S., Scadden, D. T. & Jain, R. K. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nature Protoc. 2, 805–810 (2007).
Segers, J. et al. Potentiation of cyclophosphamide chemotherapy using the antiangiogenic drug thalidomide: Importance of optimal scheduling to exploit the normalization window of the tumor vasculature Cancer Lett. 244, 129–135 (2006).
Batchelor, T. T. et al. A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Proc. Am. Assoc. Cancer Res. Ann. Meeting Abstract 5531 (2008).
Horowitz, N. S. et al. A multidisciplinary phase II study of bevacizumab combined with oxaliplatin, gemcitabine in women with recurrent mullerian carcinoma. Proc. Am. Assoc. Cancer Res. Ann. Meeting Abstract 4484 (2008).
Willett, C. G. et al. Evaluation of the effects of anti-VEGF therapy in a multidisciplinary phase I/II study of neoadjuvant bevacizumab with chemoradiation therapy in rectal cancer. Proc. Am. Assoc. Cancer Res. Ann. Meeting Abstract 4457 (2008).
Zhu, A. X. et al. Efficacy, safety, and changes in blood markers following sunitinib monotherapy in patients with advanced hepatocellular carcinoma: Experience from a multidisciplinary phase II study. Proc. Am. Assoc. Cancer Res. Ann. Meeting Abstract 4464 (2008).
Giantonio, B. J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25, 1539–1544 (2007).
Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).
Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542–2550 (2006).
Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007).
Motzer, R. J. et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).
Willett, C. G. et al. Complete pathological response in T4 locally advanced rectal cancer after treatment with bevacizumab and standard chemo-radiotherapy. Nature Clin. Pract Oncol. 4, 316–321 (2007).
Horsman, M. R. & Siemann, D. W. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res., 66, 11520-11539 (2006).
Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932–936 (2005).
Ellis, L. M. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin. Oncol. 33, S1–7 (2006).
Jain, R. K., Duda, D. G., Clark, J. W. & Loeffler, J. S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clin. Pract Oncol. 3, 24–40 (2006).
Kerbel, R. S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312, 1171–1175 (2006).
Verheul, H. M. W. & Pinedo, H. M. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nature Rev. Cancer 7, 475–485 (2007).
Dvorak, H. F. Discovery of vascular permeability factor (VPF). Exp. Cell Res. 312, 522–526 (2006).
Jain, R. K. et al. Angiogenesis in brain tumours. Nature Rev. Neurosci. 8, 610–622 (2007).
Sorensen, A. G., Batchelor, T. T., Wen, P. Y., Zhang, W. T. & Jain, R. K. Response criteria in glioma. Nature Clin. Pract Oncol. (in the press).
Ferrara, N., Damico, L., Shams, N., Lowman, H. & Kim, R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26, 859–870 (2006).
Jain, R. K., Finn, A. V., Kolodgie, F. D., Gold, H. K. & Virmani, R. Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. Nature Clin. Pract. Cardiovasc. Med. 4, 491–502 (2007).
Jain, R. K. & Carmeliet, P. F. Vessels of death or life. Sci. Am. 285, 38–45 (2001).
Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nature Rev. Drug Discov. 6, 273–286 (2007).
Jain, R. K. Barriers to drug delivery in solid tumors. Sci. Am. 271, 58–65 (1994).
Jain, R. K. & Baxter, L. T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 48, 7022–7032 (1988).
Gutmann, R. et al. Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res. 52, 1993–1995 (1992).
Less, J. R., Skalak, T. C., Sevick, E. M. & Jain, R. K. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res. 51, 265–273 (1991).
Less, J. R., Posner, M. C., Skalak, T., Wolmark, N. & Jain, R. K. Geometric resistance to blood flow and vascular network architecture in human colorectal carcinoma. Microcirculation 4, 25–33 (1997).
Mouta Carreira, C. et al. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res. 61, 8079–8084 (2001).
I would like to thank the clinical team leaders (T. T. Batchelor, A. G. Sorensen and C. G. Willett) and all the co-investigators of these two studies: from the Steele Lab (Y. Boucher, E. di Tomaso, D. G. Duda, K. R. Kozak, S. V. Kozin, L. L. Munn and R. Tong); from the Departments of Radiology (T. Benner, P. J. Chen, A. Fischman, S. Kalva, D. Sahani, W.-T. Zhang and M. Zhu), Radiation Oncology (M. Ancukiewicz, A. Hartford, and J. S. Loeffler), Medicine (D. Chung), Pathology (G. Lauwers, D. Louis and M. Mino-Kenudson), Surgery (P. Shellito), Haematology–Oncology (Blaszkowsky, J. Clark, K. S. Cohen, D. P. Ryan, D. T. Scadden, and A. X. Zhu) and Neurooncology (D. Cahill, J. Drappatz, M. M. Mrugala, S. Plotkin and P. Y. Wen). Many thanks to our technicians and nurses, the National Institutes of Health, the National Foundation for Cancer Research and the Montesi Family Fund for support, to all members of the Steele Lab, especially D. Fukumura and L. Xu for collaboration in the area of angiogenesis, to D. G. Duda and E. di Tomaso for their help with the manuscript preparation and to T. T. Batchelor, B. Chabner, D. G. Duda, R. Gaynor, J. S. Loeffler, J. A. Samson, A. G. Sorensen, H. D. Suit and C. G. Willett for their helpful comments on this manuscript. A special tribute goes to all the patients enrolled in these studies, and to their families and friends.
Declaration: Rakesh K. Jain is a consultant and grant recipient of AstraZeneca, a consultant of Dyax and on the scientific advisory board of SynDevRx.
National cancer institute
National cancer institute Drug Dictionary
About this article
Cite this article
Jain, R. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 8, 309–316 (2008). https://doi.org/10.1038/nrc2346
This article is cited by
The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients
Journal of Neuro-Oncology (2022)
Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer
Abdominal Radiology (2020)
Synthesis and evaluation of a novel series of 6-bromo-1-cyclopentyl-1H-indazole-4-carboxylic acid-substituted amide derivatives as anticancer, antiangiogenic, and antioxidant agents
Medicinal Chemistry Research (2020)
6-Gingerol stabilized the p-VEGFR2/VE-cadherin/β-catenin/actin complex promotes microvessel normalization and suppresses tumor progression
Journal of Experimental & Clinical Cancer Research (2019)
Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer
International Journal of Clinical Oncology (2017)